ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1905

Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

Joel Kremer1, William F C Rigby2, Nora Singer3, Christine Birchwood4, Darcy Gill4, William Reiss4, Jinglan Pei4 and Margaret Michalska4, 1Albany Medical College, Albany, NY, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Genentech, Inc., South San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-TNF therapy, Biologics, methotrexate (MTX), rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Trials Therapy

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance or to reduce medication burden. This study evaluated whether tocilizumab-monotherapy (TCZ-MONO) is non-inferior to TCZ + MTX in maintaining clinical response in patients who achieve low disease activity with TCZ + MTX in the COMP-ACT trial.

 

Methods: US patients with RA who were inadequate responders to MTX initially received MTX (≥ 15 mg/week orally) plus TCZ 162 mg subcutaneous (SC) either weekly (patients ≥ 100 kg) or every 2 weeks (patients < 100 kg). Patients who had not achieved low disease activity (DAS28 ≤ 3.2) at week 12 could escalate from q2w to qw dosing. Patients who achieved DAS28-ESR ≤ 3.2 at week 24 were randomized 1:1 to receive TCZ-MONO or TCZ + MTX until week 52 (double-blind). The primary outcome measured was the comparison of mean change in DAS28-ESR score from weeks 24 to 40 between the TCZ-MONO and TCZ + MTX arms (non-inferiority margin of 0.6). Secondary outcomes included the proportion of patients achieving DAS28 < 2.6, DAS28 ≤ 3.2 and American College of Rheumatology 20%/50%/70% (ACR20/50/70) responses at weeks 40 and 52, and safety. Trial registration number: NCT01855789.

 

Results: Of 718 patients enrolled, 296 were randomized at week 24 (TCZ-MONO, n = 148; TCZ + MTX, n = 148). Early discontinuation in the randomized cohort occurred in 12.2% of patients in the TCZ-MONO group and 10.2% in the TCZ + MTX group. Baseline characteristics were balanced between treatment groups (mean age, 55.5 years; 74.8% female; mean RA duration, 6.8 years; mean DAS28-ESR, 6.3). At week 24, DAS28 scores were similar in both groups, but ACR responses were ≈8% to 11% lower in the TCZ-MONO group prior to MTX withdrawal (randomization). The mean change in DAS28 was similar between the randomized treatment groups (Table 1). For the primary efficacy analysis, the mean changes in DAS28 from weeks 24 to 40 were 0.46 and 0.14 in the TCZ-MONO and TCZ + MTX groups, respectively (95% CI, 0.045-0.592). This study met the primary endpoint by demonstrating that discontinuing MTX in TCZ responders was noninferior to continuing MTX. The safety of TCZ-SC in this study was consistent with the known safety profile, with no new safety signals observed (Table 2). The most common SAE was infection, occurring in 4.1% of patients. TCZ + MTX had greater frequency of AEs, SAEs and serious infections than TCZ-MONO.

 

Conclusion: These results demonstrate that patients receiving TCZ + MTX who achieve low disease activity can discontinue MTX and maintain disease control.

 

Table 1. Efficacy of TCZ as Monotherapy and in Combination With MTX

 

TCZ-MONO

(n = 147)

TCZ + MTX

(n = 147)

Difference (95% CI)

(TCZ-MONO minus

TCZ + MTX)

ΔDAS28-ESR, mean (SEM)*

Week 24 to week 40

0.46 (0.123)

0.14 (0.126)

0.318 (0.045, 0.592)

Week 24 to week 52

0.43 (0.136)

0.20 (0.139)

0.232 (−0.068, 0.532)

Response at Week 40, n (%)

DAS28 ≤ 3.2

94 (63.9)

113 (76.9)

−12.9 (−23.3, −2.6)

DAS28 < 2.6

74 (50.3)

87 (59.2)

−8.8 (−20.2, 2.5)

ACR20

103 (70.1)

116 (78.9)

−8.8 (−18.8, 1.1)

ACR50

76 (51.7)

94 (63.9)

−12.2 (−23.4, −1.0)

ACR70

51 (34.7)

62 (42.2)

−7.5 (−18.6, 3.6)

DAS28 Worsening ≥ 1.2, n (%)

Week 24 to week 40

42 (28.6)

31 (21.1)

7.5

(−2.4, 17.3)

ACR, American College of Rheumatology criteria; AE, adverse event; DDAS28-ESR, change in Disease Activity Score-28 joints erythrocyte sedimentation rate; MTX, methotrexate; SAE, serious adverse events; SEM, standard error of the mean; TCZ, tocilizumab; TCZ+MTX, TCZ plus MTX; TCZ-MONO, TCZ monotherapy.

* Adjusted means from ANCOVA model include week 24 DAS28 as a covariate, treatment group and the randomization stratification factors: DAS28 remission status at week 24 (< 2.6; ≥ 2.6 to ≤ 3.2), patient anti-TNF exposure (Yes/No), baseline weight-by-dosing group (< 80 kg q2w; < 80 kg qw; 80 to < 100 kg q2w; 80 to < 100 kg qw, ≥ 100 kg qw). Last observation carried forward (LOCF) was used to impute missing data at week 40 only.

 

 

Table 2. Safety of TCZ as Monotherapy and in Combination With MTX

Rate, per 100 PY (95% CI)

Total* N = 713 700.60 PY

TCZ-MONO†

n = 144

92.44 PY

TCZ + MTX†

n = 139

90.56 PY

AEs

377.1

(362.9, 391.8)

238.0

(207.6, 271.6)

308.1

(273.0, 346.4)

SAEs

17.0

(14.1, 20.3)

8.7

(3.7, 17.1)

14.4

(7.6, 24.6)

Serious infections

5.0

(3.5, 7.0)

3.3

(0.7, 9.5)

4.4

(1.2, 11.3)

AE, adverse event; MTX, methotrexate; PBO, placebo; PY, patient-year; SAE, serious adverse event; TCZ, tocilizumab; TCZ+MTX, TCZ plus MTX; TCZ-MONO, TCZ monotherapy.

* Safety population from baseline to end of study.

† Includes all randomized patients who were administered TCZ+MTX or TCZ+PBO from week 24 to end of study.

 


Disclosure: J. Kremer, Corrona, LLC, 1,Corrona, LLC, 3,AbbVie, Amgen, BMS, Genentech, Lilly, Regeneron, Sanofi, Pfizer, 5,AbbVie, Genentech, Lilly, Novartis, Pfizer, 2; W. F. C. Rigby, Roche/Genentech, 5; N. Singer, Merck, EMD Serono, 2,Pfizer Inc, 5; C. Birchwood, Genentech, Inc., 3; D. Gill, Genentech, Inc., 3; W. Reiss, Genetech, Inc., 3; J. Pei, Genentech, Inc., 3; M. Michalska, Genetech, Inc., 3.

To cite this abstract in AMA style:

Kremer J, Rigby WFC, Singer N, Birchwood C, Gill D, Reiss W, Pei J, Michalska M. Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/sustained-response-following-discontinuation-of-methotrexate-in-patients-with-rheumatoid-arthritis-treated-with-subcutaneous-tocilizumab-results-from-a-randomized-controlled-trial/. Accessed June 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-response-following-discontinuation-of-methotrexate-in-patients-with-rheumatoid-arthritis-treated-with-subcutaneous-tocilizumab-results-from-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies